Amphastar Pharmaceuticals stock forecast
Amphastar Pharmaceuticals (29A) Stock Forecast & Price Target
29A Analyst Ratings
29A Stock 12 Month Forecast
Average Price Target
€22.52▼(-12.19% Downside)Detailed List of Analyst Forecasts
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Benjamin Burnett | Wells Fargo | €17.84→€22.30 | hold | -13.06%Downside | Reiterated | 11/06/26 | ||
| Jason Gerberry | Bank of America Securities | €20.52 | sell | -20.01%Downside | Reiterated | 11/06/26 | ||
 Unknown AnalystNot Ranked | J.P. Morgan | €26.76 | hold | 4.33%Upside | Reiterated | 10/22/26 | ||
| Glen Santangelo | Barclays | €17.84→€20.52 | hold | -20.01%Downside | Reiterated | 08/18/26 | ||
| David Amsellem | Piper Sandler | €18.73→€17.84 | hold | -30.44%Downside | Reiterated | 08/07/26 | ||
| Serge Belanger | Needham | €17.84 | hold | -30.44%Downside | Reiterated | 08/07/26 | ||
| Dennis Ding | Jefferies | €26.76→€19.63 | hold | -23.49%Downside | Downgraded | 04/21/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Benjamin BurnettWells Fargo | HoldReiterated€17.84→€22.30 | 11/06/26 | -13.06%Downside | ||
| Jason GerberryBank of America Securities | SellReiterated€20.52 | 11/06/26 | -20.01%Downside | ||
| Unknown AnalystJ.P. MorganNot Ranked | HoldReiterated€26.76 | 10/22/26 | 4.33%Upside | ||
| Glen SantangeloBarclays | HoldReiterated€17.84→€20.52 | 08/18/26 | -20.01%Downside | ||
| David AmsellemPiper Sandler | HoldReiterated€18.73→€17.84 | 08/07/26 | -30.44%Downside | ||
| Serge BelangerNeedham | HoldReiterated€17.84 | 08/07/26 | -30.44%Downside | ||
| Dennis DingJefferies | HoldDowngraded€26.76→€19.63 | 04/21/26 | -23.49%Downside |
Best Analysts Covering Amphastar Pharmaceuticals
Copying xAi Drug Manufacturers - Specialty and Generic's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +2.45% per trade.
Copying xAi Drug Manufacturers - Specialty and Generic's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +2.45% per trade.
Copying xAi Drug Manufacturers - Specialty and Generic's trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +2.45% per trade.
29A Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 7 | 7 | 7 | 6 | 3 |
| Sell | 1 | 2 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 8 | 9 | 8 | 7 | 4 |
In the current month, 29A has received 0 Buy Ratings, 3 Hold Ratings, and 1 Sell Ratings. 29A average Analyst price target in the past 3 months is 22.52.
29A Financial Forecast
29A Earnings Forecast
Next quarter’s earnings estimate for 29A is EUR 0.70 with a range of EUR 0.47 to EUR 0.90. The previous quarter’s EPS was EUR 1.02. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
29A Sales Forecast
Next quarter’s sales forecast for 29A is EUR 175.25M with a range of EUR 163.85M to EUR 182.65M. The previous quarter’s sales results were EUR 185.88M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
